In a research report published Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $7.
In a research report released Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR) with a price …
Cempra Inc (NASDAQ:CEMP) shares went on a roller-coaster ride today after the FDA’s Antimicrobial Drugs Advisory Committee voted 7-6 that solithromycin’s efficacy outweighs its risks …
Palatin Technologies, Inc. (NYSEMKT:PTN) shares were on a close to 18% rise after market close yesterday after the firm’s pipeline drug bremelanotide (BMT), …
In a research report released Wednesday, Roth Capital analyst Philip Shen reiterated a Neutral rating on shares of Enphase Energy Inc (NASDAQ:ENPH), while slashing …
With Glu Mobile Inc. (NASDAQ:GLUU) preparing to release third-quarter earnings on Thursday, November 3, Roth Capital analyst Darren Aftahi weighs in with his expectations.
In a research report released Friday, Roth Capital analyst William Gibson reiterated a Neutral rating on shares of xG Technology Inc (NASDAQ:XGTI), with a price …
Cerulean Pharma Inc Cerulean Pharma Inc (NASDAQ:CERU) shares jumped nearly 47% today after the company announced that it has entered into a research …
In a research report released today, Roth Capital analyst Michael Higgins resumed coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a Neutral rating on …
Roth Capital analyst Scott Henry is out today with a research note on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), following recent meeting with the company’s senior management. …
